Top MarketRank™ StocksTop MarketRank™NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis $20.97 -0.05 (-0.24%) Closing price 04:00 PM EasternExtended Trading$21.00 +0.04 (+0.17%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CPRX alerts:Sign Up Key Stats Today's Range$20.72▼$21.1450-Day Range$20.75▼$26.3152-Week Range$15.34▼$26.58Volume908,559 shsAverage Volume1.29 million shsMarket Capitalization$2.56 billionP/E Ratio13.36Dividend YieldN/APrice Target$32.83Consensus RatingBuy Company Overview Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida. Read More Catalyst Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreCPRX MarketRank™: Catalyst Pharmaceuticals scored higher than 98% of companies evaluated by MarketBeat, and ranked 25th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCatalyst Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Catalyst Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth12.11% Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 12.11% in the coming year, from $1.90 to $2.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 13.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 13.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.07.Price to Earnings Growth RatioCatalyst Pharmaceuticals has a PEG Ratio of 0.88. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Catalyst Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.48% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 5.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-1.99 Percentage of Shares Shorted7.48% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 5.69%, indicating that investor sentiment is decreasing significantly. News and Social Media3.5 / 5News Sentiment1.34 News SentimentCatalyst Pharmaceuticals has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Catalyst Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest22 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,879,369.00 in company stock.Percentage Held by Insiders10.40% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Catalyst Pharmaceuticals' insider trading history. Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Stock News HeadlinesCatalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025July 22 at 8:03 AM | globenewswire.comCatalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gainsJuly 16, 2025 | marketwatch.comAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this marks the beginning of “Trump’s Great Gain,” a new crypto bull phase driven by emerging federal policies. He believes certain altcoins could turn $900 into $108,000 — and reveals everything in a new presentation.July 25 at 2:00 AM | Paradigm Press (Ad)Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - NasdaqJuly 9, 2025 | nasdaq.comCatalyst Pharmaceuticals, Inc. (CPRX) Cash Flow - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comCatalyst Pharmaceuticals is Now Oversold (CPRX) - NasdaqJuly 2, 2025 | nasdaq.comAre Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? - NasdaqJuly 2, 2025 | nasdaq.comCPRX - Catalyst Pharmaceuticals Inc Financials - MorningstarJune 25, 2025 | morningstar.comMSee More Headlines CPRX Stock Analysis - Frequently Asked Questions How have CPRX shares performed this year? Catalyst Pharmaceuticals' stock was trading at $20.87 on January 1st, 2025. Since then, CPRX shares have increased by 0.0% and is now trading at $20.8750. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 EPS for the quarter, hitting the consensus estimate of $0.10. The biopharmaceutical company earned $35.95 million during the quarter, compared to the consensus estimate of $34.47 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 42.45% and a net margin of 36.91%. Read the conference call transcript. Who are Catalyst Pharmaceuticals' major shareholders? Top institutional shareholders of Catalyst Pharmaceuticals include Aberdeen Group plc (0.56%), Assenagon Asset Management S.A. (0.09%), Campbell Newman Asset Management Inc. (0.08%) and Juncture Wealth Strategies LLC (0.07%). Insiders that own company stock include Patrick J Mcenany, Steve Miller, David S Tierney, Donald A Denkhaus, Richard J Daly, Brian Elsbernd, Philip H Coelho, Gary Ingenito, Alicia Grande, Preethi Sundaram, Carmen Jeffrey Del and Molly Harper. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings11/09/2021Today7/25/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CPRX CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees80Year Founded2002Price Target and Rating Average Price Target for Catalyst Pharmaceuticals$32.83 High Price Target$36.00 Low Price Target$30.00 Potential Upside/Downside+56.9%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$1.57 Trailing P/E Ratio13.32 Forward P/E Ratio11.01 P/E Growth0.88Net Income$163.89 million Net Margins36.91% Pretax Margin48.34% Return on Equity42.45% Return on Assets36.59% Debt Debt-to-Equity RatioN/A Current Ratio6.14 Quick Ratio5.96 Sales & Book Value Annual Sales$534.65 million Price / Sales4.77 Cash Flow$2.37 per share Price / Cash Flow8.82 Book Value$6.10 per share Price / Book3.43Miscellaneous Outstanding Shares121,975,000Free Float109,290,000Market Cap$2.55 billion OptionableOptionable Beta0.66 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CPRX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.